BioCytics and LIDE Biotech Collaborate to Advance Cancer Therapies through Innovative Screening Platforms

Strategic Alliance Between BioCytics and LIDE Biotech

In a groundbreaking collaboration, BioCytics, Inc., and LIDE Biotech have announced a strategic partnership focused on developing innovative screening platforms and companion diagnostics specifically for immune-based cancer cell therapies. This collaboration marks an essential step forward in the quest for personalized medicine solutions in the realm of oncology.

Uniting Expertise for Cancer Treatment Innovation

The partnership combines the strengths of BioCytics' specialized cell manufacturing capabilities with LIDE's proprietary patient-derived xenograft technologies, including PDX, MiniPDX®, and immune-oncology based PDX models. This potent alliance aims to accelerate the development of immuno-oncology treatments that are critical in addressing various forms of cancer.

The initial project, made possible by a recently executed Memorandum of Understanding, will focus on creating murine PDX models derived from human biospecimens collected ethically from consented patients. This effort is linked to an ongoing institutional review board (IRB)-approved study initiated by BioCytics, which has been in progress since 2007. It is anticipated that these tumor models will provide vital insights into drug resistance and cell death dynamics, which are crucial to enhancing treatment protocols.

Researching Critical Responses

Being able to observe critical responses such as drug resistance and induced cell death is paramount for the cells being treated in in vivo validation studies. The collaboration also plans to delve into DNA and RNA sequencing, which will aid in studying human anti-tumor immune responses, further enriching the research landscape in personalized oncology.

Dr. Brent Dixon, the Chief Operating Officer of BioCytics, expressed his enthusiasm about the partnership, stating, "Working with LIDE Biotech enables real breakthroughs in personalized medicine for cancer patients. We are excited about exploring our developments for autologous adaptive immune cell therapy within this unique model. We expect to learn more about the essential molecular pathways and signatures based on the applied analytical methodologies."

Dr. Danyi Wen, the Founder and CEO of LIDE Biotech, echoed Dr. Dixon's sentiments, emphasizing the significance of this collaboration: "LIDE is excited for its first-ever partnership with an American-based company to further deliver on our goals to support translational research for new drug R&D and personalized oncology." She added, "We are looking forward to working with BioCytics and leveraging its expertise to make LIDE technologies available outside of China. BioCytics' patient-first vision is inspiring and truly aligns with LIDE's mission to empower more scientists, accelerate breakthroughs, and help bring promising treatments closer to patients in need."

A New Era in Personalized Medicine

BioCytics, which operates from Huntersville, North Carolina, has been at the forefront of health technology since its inception in 2005 by Dr. John Powderly. The company is dedicated to developing Autologous Adaptive Immune Cell Therapy (AAICT), offering an innovative approach to treating solid tumors with patients' own immune cells. This revolutionary point-of-care manufacturing process is designed to create nongenetically modified effector cell fractions, applicable to all stages of solid tumors.

LIDE Biotech, founded in Shanghai in 2011 by Dr. Wen, operates as a preclinical oncology Contract Research Organization (CRO) with a keen focus on translational research. The company boasts a vast library of more than 2300 PDX models covering over 40 cancer types, aiming to bring preclinical studies closer to clinical relevance. Their expertise allows them to provide gold-standard preclinical drug validation tools leveraging a strong network within the translational hospital ecosystem.

This collaboration between BioCytics and LIDE Biotech has the potential to significantly impact the future of cancer therapies, taking personalized medicine to new heights and offering fresh hope to patients suffering from various malignancies. Together, they are poised to make strides that could redefine treatment pathways and enhance the outcomes for cancer patients worldwide.